Bicara Therapeutics (BCAX) Invested Capital (2023 - 2026)

Bicara Therapeutics has reported Invested Capital for 4 years, with the latest figure at $514.0 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 11.98% year-over-year to $514.0 million; the trailing twelve-month figure through Mar 2026 stood at $514.0 million (up 11.98% YoY), and the FY2025 full-year result was $401.5 million, down 18.38% from the prior year.
• Invested Capital for Q1 2026 stood at $514.0 million, up from $401.5 million in the prior quarter.
• The five-year high for Invested Capital was $514.0 million in Q1 2026, with the low at -$174.8 million in Q2 2024.
• Historically, Invested Capital has averaged $235.7 million across 4 years, with a median of $402.8 million in 2025.
• Annual changes were most pronounced in 2024 — Invested Capital soared 471.64% — and 2025, when it fell 20.95%.
• Bicara Therapeutics' Invested Capital stood at -$148.8 million in 2023, then surged by 430.63% to $491.9 million in 2024, then declined by 18.38% to $401.5 million in 2025, then rose by 28.02% to $514.0 million in 2026.
• The last three Invested Capital figures came in at $514.0 million (Q1 2026), $401.5 million (Q4 2025), and $402.8 million (Q3 2025), per Business Quant data.